Heme Today editors highlight major news on classical hematology, with a focus on MDS research, from the 66th American Society of Hematology Annual Meeting & Exposition, hosted December 7-10, 2024, in San Diego, California.
Advertisement
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The positive predictive value for cancer was 15% higher for those enrolled.
Bidirectional Mendelian randomization was used and a multi-trait analysis of GWAS was conducted.
The burden of disease is expected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence in kidney care.
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
The Latest From Heme Today
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
A transcriptomic analysis saw CDK8 repression increase expression of myeloid differentiation and oncogenesis genes in HSPCs.
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
The investigators compiled patients' quality of life, social function, and physical scores, and assessed overall survival.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.